Examining product risk in context. Market withdrawal of zomepirac as a case study.
暂无分享,去创建一个
S B Soumerai | D Ross-Degnan | J. Gurwitz | S. Soumerai | D. Ross-Degnan | E. Fortess | J H Gurwitz | E E Fortess
[1] D. Knapp,et al. Utilization of analgesic drugs in office-based ambulatory care: National Ambulatory Medical Care Survey, 1980-81. , 1984, Advance data.
[2] R. Shochet,et al. Analytic Reviews : Neuropsychiatric Toxicity of Meperidine , 1988 .
[3] G. Heidrich,et al. Central nervous system excitatory effects of meperidine in cancer patients , 1983, Annals of neurology.
[4] W. Ray,et al. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. , 1992, Journal of gerontology.
[5] S B Soumerai,et al. Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. , 1990, JAMA.
[6] V. Smith. Anaphylactic shock, acute renal failure, and disseminated intravascular coagulation. Suspected complications of zomepirac. , 1982, JAMA.
[7] M. Henman,et al. Impact of a Nationwide Limited Prescribing List: Preliminary Findings , 1987, Drug intelligence & clinical pharmacy.
[8] K. Corre,et al. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point. , 1988, Annals of emergency medicine.
[9] J. Avorn,et al. Improving drug prescribing in primary care: a critical analysis of the experimental literature. , 1989, The Milbank quarterly.
[10] J. Avorn,et al. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. , 1987, American Journal of Public Health.
[11] D. Brahams. Triazolam suspended , 1991, The Lancet.
[12] B. Strom,et al. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. , 1987, Arthritis and rheumatism.
[13] J. Avorn,et al. Physician motivations for nonscientific drug prescribing. , 1989, Social science & medicine.
[14] W. Barclay. AMA drug evaluations. , 1977, JAMA.
[15] Stephen B. Soumerai,et al. Payment Restrictions for Prescription Drugs under Medicaid , 1987 .
[16] D. Makuc,et al. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. , 1981, American journal of public health.
[17] S. Soumerai,et al. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. , 1993, The Milbank quarterly.
[18] M. Weintraub,et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. , 1991, JAMA.
[19] E. Lesnefsky,et al. Near fatal bronchospasm induced by zomepirac sodium. , 1982, Annals of allergy.
[20] D. Kennedy,et al. Utilization of nonsteroidal antiinflammatory drugs. , 1985, Arthritis and rheumatism.
[21] Erwin K. Kastrup,et al. Drug facts and comparisons , 1977 .
[22] S. Gortmaker,et al. Reducing infant mortality in rural America: evaluation of the Rural Infant Care Program. , 1987, Health services research.
[23] A. Mack,et al. Effect of regulatory withdrawal of drugs and prescription recommendations on the pattern of self-poisonings in Oslo. , 2009, Acta medica Scandinavica.
[24] S B Soumerai,et al. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. , 1987, The New England journal of medicine.
[25] Smith Vt. Anaphylactic Shock, Acute Renal Failure, and Disseminated Intravascular Coagulation: Suspected Complications of Zomepirac , 1982 .
[26] S. Soumerai,et al. Effects of professional and media warnings about the association between aspirin use in children and Reye's syndrome. , 1992, The Milbank quarterly.